Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 53.40M | 65.49M | 47.64M | 38.35M | 62.90M |
Gross Profit | 29.08M | 42.51M | 28.05M | 22.00M | 52.02M |
EBITDA | 6.52M | 12.94M | -10.78M | -18.94M | 4.45M |
Net Income | 2.93M | 8.31M | -14.93M | -27.58M | -6.52M |
Balance Sheet | |||||
Total Assets | 73.42M | 84.43M | 55.79M | 73.67M | 67.93M |
Cash, Cash Equivalents and Short-Term Investments | 34.83M | 44.56M | 22.18M | 38.98M | 38.55M |
Total Debt | 5.53M | 26.28M | 33.47M | 33.47M | 64.40M |
Total Liabilities | 30.21M | 50.87M | 66.43M | 79.70M | 94.97M |
Stockholders Equity | 43.21M | 33.57M | -10.64M | -6.04M | -27.04M |
Cash Flow | |||||
Free Cash Flow | 7.39M | -2.47M | -25.63M | -11.74M | -26.76M |
Operating Cash Flow | 8.67M | -1.32M | -25.00M | -10.29M | -26.11M |
Investing Cash Flow | 4.22M | -16.71M | -5.04M | 18.92M | -19.95M |
Financing Cash Flow | -16.79M | 24.67M | 8.24M | 12.08M | 46.47M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $123.39M | 36.90 | 10.42% | ― | 0.18% | -55.15% | |
59 Neutral | $439.45M | ― | -86.09% | ― | 1250.63% | 37.24% | |
54 Neutral | $266.86M | ― | -198.47% | ― | ― | -38.86% | |
46 Neutral | C$201.68M | -3.28 | -23.14% | 1.87% | 20.75% | -0.36% | |
45 Neutral | $531.89M | ― | -32.12% | ― | ― | 10.98% | |
36 Underperform | $132.20M | ― | -244.16% | ― | ― | 77.12% | |
35 Underperform | $425.06M | ― | -500.57% | ― | ― | 81.94% |
On July 21, 2025, Protalix BioTherapeutics announced the appointment of Gilad Mamlok as the new Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin. Mamlok, with three decades of experience in healthcare and technology sectors, is expected to play a crucial role in executing Protalix’s growth strategy. The transition is designed to be seamless with Rubin assisting until October 2025. This leadership change is anticipated to strengthen Protalix’s financial and operational strategies, further solidifying its position in the biopharmaceutical industry.
The most recent analyst rating on (PLX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.
On June 26, 2025, Protalix Biotherapeutics, Inc. held its Annual Meeting of Stockholders in Tel Aviv, Israel. During the meeting, stockholders elected eight board members, approved executive compensation on a non-binding basis, and ratified the appointment of Kesselman & Kesselman as the independent accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (PLX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.